drugset / Trial / NCT06931626
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.
Timeline
- Start
- 2025-08-15
- Primary completion
- 2026-10-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NMS-03305293 | Unknown | 100 mg | Oral |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |